How people with CF access CFTR modulators in countries where coverage is not provided by health systems
The impact of elexacaftor/tezacaftor/ivacaftor on anxiety and depression in adults with Cystic Fibrosis
Eradication of Nontuberculous Mycobacteria in People with Cystic Fibrosis Treated with Elexacaftor/Tezacaftor/Ivacaftor
Predicting Risk-Adjusted Incidence Rates of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in the Cystic Fibrosis Programs in the United States
